PERSON – Page 15

Tenpoint Therapeutics Announces Breakthrough Phase 3 Results for Presbyopia Treatment Following Merger with Visus

4 months ago talkbio0Tagged BRIMOCHOL, Eye, fluorouracil/melphalan, Phase 3 trial, presbyopia, Tenpoint Therapeutics, vision drug, Visus merger

Tenpoint Therapeutics, Visus merger, Phase 3 trial, presbyopia treatment, BRIMOCHOL PF, vision drug, ophthalmic therapeutics

Mendaera Appoints Eric Davidson as Chief Commercial Officer to Lead Handheld Medical Robot Launch

4 months ago talkbio0Tagged Aortic Valve Insufficiency, Commercial Officer, Eric Davidson, handheld medical robot, Interventional radiology, medical robotics, Mendaera

Mendaera, handheld medical robot, chief commercial officer, Eric Davidson, medical robotics, AI, interventional radiology

Breakthrough in Graft-Versus-Host Disease Treatment: MaaT013 Microbiome Therapy Shows Unprecedented Efficacy

4 months ago talkbio0Tagged acute, Fecal Microbiota Transplantation, Graft-Versus-Host Disease, GvHD, MaaT013, Microbiome Therapy, Precision - temporal, Science of nutrition, Steroid-Resistant

Graft-Versus-Host Disease (GvHD), Microbiome Therapy, MaaT013, Acute GvHD, Steroid-Resistant GvHD, Faecal Microbiota Transplantation, Precision Nutrition

Capsida and AbbVie’s Gene Therapy Collaboration Yields Promising Results for Eye Diseases

4 months ago talkbio0Tagged AbbVie, Capsida Biotherapeutics, Dependovirus, gene therapy, genetic medicines, Ophthalmology specialty, strategic collaboration

Capsida Biotherapeutics, AbbVie, gene therapy, eye diseases, strategic collaboration, adeno-associated virus (AAV) engineering platform, ophthalmology, genetic medicines.

Moderna CEO Reflects on 2024 Challenges and Advances in Shareholder Letter

4 months ago talkbio0Tagged 2024, COVID19 (disease), Letter [Publication Type], Moderna, mRNA medicines, Respiratory syncytial virus, Review [Publication Type], shareholder, Stéphane Bancel, Vaccines

Moderna, shareholder letter, 2024 review, RSV vaccine, COVID-19 vaccine, mRNA medicines, Stéphane Bancel

I-Mab Reprioritizes Pipeline, Halts CD73 Antibody Development to Focus on Givastomig

4 months ago talkbio0Tagged 5'-NUCLEOTIDASE, Antibodies, Antibodies, Bispecific, Givastomig, I-Mab, Immunotherapy for cancer, metastatic gastric cancers, pipeline, reshuffle, Uliledlimab

I-Mab, pipeline reshuffle, CD73 antibody, uliledlimab, givastomig, CLDN18.2 x 4-1BB bispecific antibody, cancer immunotherapy, metastatic gastric cancers

I-Mab Shifts Focus Away from CD73 Program to Pursue Strategic Options in CLDN18.2 Space

4 months ago talkbio0Tagged 5'-NUCLEOTIDASE, biotech, development aspects, I-Mab, sanofi, Strategic Options

I-Mab, CD73, CLDN18.2, Sanofi, Strategic Options, Biotech Development

WuXi AppTec Divests Cell and Gene Therapy Units to Altaris in Strategic Shift

4 months ago talkbio0Tagged Altaris ', AppTec, Cells, gene therapy, Pharmaceutical Outsourcing, Strategic Divestment, WuXi

WuXi AppTec, Cell and Gene Therapy, Altaris, Strategic Divestment, Biosecure Act, Pharmaceutical Outsourcing

Cobenfy: A Breakthrough in Schizophrenia Treatment with a Novel Mechanism of Action

4 months ago talkbio0Tagged Antipsychotic Agents, Approved, Cobenfy, Muscarinic Acetylcholine Receptor, Myers, Schizophrenia, squibb, trospium chloride, United States Food and Drug Administration, xanomeline

Cobenfy, schizophrenia, muscarinic receptors, xanomeline, trospium chloride, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, antipsychotic drugs.

FDA Approves Zepbound for Obstructive Sleep Apnea in Adults with Obesity

4 months ago talkbio0Tagged Approved, Obesity, Sleep Apnea, Obstructive, United States Food and Drug Administration, Zepbound

Zepbound, FDA approval, obstructive sleep apnea, obesity, tirzepatide, sleep disorder treatment